Jordi Lesbordes

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Leukemia is the most common blood cancer, and its development starts at diverse points, leading to distinct subtypes that respond differently to therapy. This heterogeneity is rarely taken into account in therapies, so it is still essential to look for new specific drugs for leukemia subtypes or even for therapy-resistant cases. Among heterocyclic compounds(More)
  • 1